ライフサイエンスコーパス: secondary leukemia

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 h chromosomal abnormalities commonly seen in secondary leukemia.

2 rimary importance in determining the risk of secondary leukemia.

3 ment of ovarian cancer increases the risk of secondary leukemia.

4 ed: two of cardiovascular disease and one of secondary leukemia.

5 early step leading to MLL translocations and secondary leukemia.

6 ntation-related complications, including two secondary leukemias.

7 nd lymphoid lineage and in treatment-induced secondary leukemias.

8 The incidence of secondary leukemia after epipodophyllotoxin treatment an

9 to obtain reliable estimates of the risk of secondary leukemia after epipodophyllotoxin treatment.

10 ative disorders, some of which progressed to secondary leukemia after long latency.

11 -induced cytotoxicity and the development of secondary leukemia after nitrosourea treatment.

12 ent with extensive prior treatment developed secondary leukemia and three became hypothyroid.

13 th respect to progression, survival, risk of secondary leukemia, and impact of genomic risk factors h

14 Secondary leukemia appeared linked with antecedent chemo

15 ty and possibly to an increased incidence of secondary leukemias as a result of elevated mutation fre

16 chromosomal translocations in patients with secondary leukemias associated with chemotherapeutic reg

17 These secondary leukemias associated with topoisomerase II inh

18 Secondary leukemia developed in five patients.

19 as a true recurrence rather than a second or secondary leukemia, DNA extracted from archived marrow s

20 Secondary leukemia emerged as a major risk with dose-int

21 tion of cumulative 6-year incidence rates of secondary leukemia for each etoposide dose group.

22 d cumulative 6-year risks for development of secondary leukemia for the low, moderate, and higher cum

23 We conducted a case-control study of secondary leukemia in a population-based cohort of 28,97

24 Cases of secondary leukemia (including treatment-related myelodys

25 cute myeloid leukemia, with the risk of this secondary leukemia linked to a genetic defect in thiopur

26 ide in adjuvant therapy and that the risk of secondary leukemia may be increased.

27 izure, neurologic impairment, limb ischemia, secondary leukemia, metastasis, or death.

28 Data obtained by the CTEP secondary leukemia monitoring plan support the relative

29 Secondary leukemias occurred in 2 patients.

30 The secondary leukemia presented as myelodysplasia with mono

31 sitive leukemia represents an outgrowth of a secondary leukemia that shares a common initiating event

32 ts treated with etoposide eventually develop secondary leukemias that are characterized by translocat

33 Disease transformation into myelofibrosis or secondary leukemia was not reported.

34 No secondary leukemia was observed.

35 No primary CNS relapse or secondary leukemia was seen.

36 All four secondary leukemias were fatal.

37 ficantly different from the expected rate of secondary leukemias when patients receive additional cyc

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。